Carmelo R.
- Country
- Italy
- Department
- Pediatric Hematology Oncology Unit
Research Overview
- Revumenib in Combination with Fludarabine and Cytarabine for Pediatric Refractory or Relapsed KMT2A-r, NUP98-r, or NPM1-mut Acute Myeloid Leukemia
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Phase 1/2 Study of Subcutaneous Blinatumomab in Adults and Adolescents with Relapsed/Refractory or MRD+ B-cell Precursor Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 172 of 277 partner sites.
Specializations
Acute Myeloid Leukemia Research
The investigator specializes in treating acute myeloid leukemia (AML), with particular focus on pediatric and young adult populations. Their expertise extends to novel therapeutic approaches for patients with FLT3 gene mutations and those with relapsed or refractory disease.
- FLT3-mutated AML interventions
- Pediatric AML treatment strategies
- Down syndrome-associated myeloid leukemia
Lymphoblastic Leukemia Studies
The investigator conducts research in acute lymphoblastic leukemia (ALL), focusing on both B-cell and T-cell variants. Their work encompasses innovative treatment approaches for high-risk and relapsed cases, including targeted therapies and immunotherapy protocols.
- CD22-positive B-cell ALL therapy
- T-cell ALL treatment strategies
- Relapsed/refractory ALL interventions
Advanced Therapeutic Approaches
The investigator explores combination therapy strategies and novel therapeutic agents, including proteasome inhibitors, tyrosine kinase inhibitors, and immunotherapeutic approaches. Their work includes studies of targeted molecular therapies for specific genetic mutations.
- Molecular-based treatment stratification
- Novel drug combinations
- Immunotherapy protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.